2023
Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
Kristensen L, Strober B, Poddubnyy D, Leung Y, Jo H, Kwok K, Vranic I, Fleishaker D, Fallon L, Yndestad A, Gladman D. Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib. Therapeutic Advances In Musculoskeletal Disease 2023, 15: 1759720x221149965. PMID: 36777695, PMCID: PMC9909057, DOI: 10.1177/1759720x221149965.Peer-Reviewed Original ResearchMajor adverse cardiovascular eventsAtherosclerotic CV diseaseTofacitinib-treated patientsAdverse cardiovascular eventsCV diseaseASCVD riskHigh blood pressurePsoriatic arthritisHigh riskHeart-related problemsHigher baselineCardiovascular eventsBlood pressureRisk calculatorIncidence rateMore casesBaseline cardiovascular riskBaseline metabolic syndromeCardiovascular disease riskJanus kinase inhibitorDose of tofacitinibGroup of conditionsBaseline MetSPsA trialsTofacitinib exposure
2022
POS1040 SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR: AS ASSESSED BY LABORATORY PARAMETERS – RESULTS FROM A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS AND 2 PHASE 3 TRIALS IN PSORIASIS
Fleischmann R, Thaçi D, Gooderham M, Strober B, Korman N, Banerjee S, Lehman T, Nowak M, Sreih A, Morita A, Mease P. POS1040 SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR: AS ASSESSED BY LABORATORY PARAMETERS – RESULTS FROM A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS AND 2 PHASE 3 TRIALS IN PSORIASIS. Annals Of The Rheumatic Diseases 2022, 81: 835.2-836. DOI: 10.1136/annrheumdis-2022-eular.1862.Peer-Reviewed Original ResearchConcomitant conventional synthetic DMARDsPhase 2 trialGrant/research supportKyowa Hakko KirinBristol-Myers SquibbCommon Terminology CriteriaPhase 3 trialSanofi GenzymeWeeks of treatmentLaboratory parametersPsoriatic arthritisLEO PharmaBoehringer IngelheimSun Pharmaceutical IndustriesUCB PharmaSpeaker feesNippon KayakuPlacebo nPsA trialsPsoriasis RegistryTerminology CriteriaWk 1Eli LillyLarge phase 3 trialsMitsubishi Tanabe